Clinical Trial Update: A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating AT-101 as a single agent in men with castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Hormone Refractory Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED